One-Plant Policy Panel @medicinal.genomics
One-Plant Policy Panel  @medicinal.genomics
Uploaded August 2026 | Updated November 2026, 3 days ago
"One-Plant Policy Panel" panel discussion at CannMed 2026, covering one-plant policy, hemp cannabis regulation, and federal cannabis policy.

As cannabis moves toward federal recognition, legalization is the entry point, not the destination. This opening panel frames the One-Plant Policy as a public-health and regulatory principle: when cannabis and hemp are intended for human consumption, they should be governed by the same safety expectations, analytical standards, and evidence thresholds, regardless of THC concentration.

Using a federal lifecycle lens of legalization, standardization, and data-validated outcomes, panelists examine how coordinated alignment across FDA, USDA, and DEA can replace fragmented state rules with harmonized oversight that protects patients and consumers, enables consistent products, and scales commerce responsibly.

Key topics include FDA regulatory lanes bridging medical cannabis, hemp-derived cannabinoids, supplements, and pharmaceuticals; protections for minors and medical patients within adult-use systems; and how U.S. legalization can catalyze Codex, USP, and ISO alignment for global markets.

Panelists:
Mike Hennesy (Moderator), Principal, Hennesy Strategy
Jordan Wellington, Managing Partner, Strategies 64
Dustin Sulak, DO, Co-Founder & Medical Director, Healer.com
Steph Sherer, Board President and Executive Director, Americans for Safe Access

This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.
One-Plant Policy PanelChronic Pain: Clinical Strategies for Success in Challenging Cases: Dustin SulakGene-Editing Frameworks for Advanced Cannabis Breeding - Angel FernandezPyrocannabinoids: An Investigation into Smoked Cannabinoid Isolates - Kristopher Marsh, PhDWhat is Thigmomorphogenesis? How Can it be Applied to Cannabis? - Dr. Jose LemeMaGiC Lysis ProcessCustom Cannabis Terpenes, Whats Your Dream Flavor?Transforming Cannabidiol: Rational Design of Next-Generation CBD Analogues for Epilepsy -Luke HodsonSynergistic Anticancer Activity of Cannabinoids & Terpenes in Triple Negative Breast CancerHow Does CBG Interact with Standard Chemotherapies? - Mandip Sachdeva, PhDCannabigerol Potentiates Chemotherapy through Multi-Modal Tumor Suppression in Pancreatic CancerRecruitment Challenges for Cannabis Clinical Trials - Emily Lindley, PhD & Rachael Rzasa Lynn, MD
Medicinal Genomics |

One-Plant Policy Panel

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER